Results 311 to 320 of about 589,804 (355)

The antibody-drug conjugate targeting ROR1, NBE-002, is active in high-grade serous ovarian cancer preclinical models. [PDF]

Ther Adv Med Oncol
Liu D, Vandenberg CJ, Sini P, Waldmeier L, Baumgartinger R, Pisarsky L, Petroczi G, Ratnayake G, Scott CL, Ford CE.   +9 more
europepmc   +1 more source

Multifunctional Biomedical Devices with Closed‐Loop Systems for Precision Therapy

Advanced Healthcare Materials, EarlyView.
This review explores two major types of closed‐loop therapeutic systems: self‐sustained and externally triggered. It highlights recent advances in stimuli‐responsive materials, integrated bioelectronics, and data‐driven control strategies, offering insight into emerging strategies for personalized, responsive drug delivery.
Yixuan Leng, Rujie Sun
wiley   +1 more source

Precise targeting cytotoxicity of antibody-drug conjugate combined with immunotherapy as first-line regimen for metastatic triple-negative breast cancer in ASCENT-04. [PDF]

Transl Breast Cancer Res
Bian L, Zhang S, Li M, Yang J, Yin Y.
europepmc   +1 more source

Spatially precise chemo-radio-immunotherapy by antibody drug conjugate directed tumor radiosensitization to potentiate immunotherapies. [PDF]

NPJ Precis Oncol
Mortaja M, Adams SR, McKay RR, Gutkind JS, Advani SJ.   +4 more
europepmc   +1 more source

Incidence of antibody-drug conjugate-related hepatotoxicity in breast cancer: a systematic review and meta-analysis. [PDF]

Ther Adv Drug Saf
Yang P, Zhang H, Li J, Li Z, Liu Z, Wang M, Zhao F, Zhao J, Shen G, Zhao Y.   +9 more
europepmc   +1 more source

The development and evaluation of a tublysine-based antibody-drug conjugate with enhanced tumor therapeutic efficacy. [PDF]

Front Pharmacol
Guo H, Xie H, Huang Y, Jia J, Kong X, Yang Q, Gai S, Li W, Bai L, Zhang L, Chen X, Ye Z, Ye H, Zhao L, Xu Y, Du Y, Zhang X, Chen M, Zhou X, Zhao RY.   +19 more
europepmc   +1 more source

Predictive Factors of Antibody-Drug Conjugate Treatment in Metastatic Breast Cancer: A Narrative Review. [PDF]

Cancers (Basel)
Gadaleta-Caldarola G, Lanotte L, Santoro AN, Pinto A, Gadaleta-Caldarola A, Giacomelli L, Fedele P.   +6 more
europepmc   +1 more source

Impact of DNA repair deficiency on sensitivity to antibody-drug conjugate (ADC) payloads in bladder cancer. [PDF]

Bladder Cancer
P Shanmugam S, Zhou Y, Stelter I, Hanlon T, Bekele RT, Bellmunt J, Szallasi Z, Mouw KW.   +7 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Sequential use of antibody-drug conjugate after antibody-drug conjugate for patients with metastatic breast cancer: ADC after ADC (A3) study.

Journal of Clinical Oncology, 2023
1022 Background: Optimizing sequential use of Antibody Drug Conjugates (ADCs) is an area of unmet need and of rising clinical importance. With the recent approvals of sacituzumab govitecan (SG) for HR+/HER2- and triple negative metastatic breast cancer ...
R. Abelman, Laura M. Spring, G. Fell, P.K. Ryan, N. Vidula, A. Medford, J. Shin, E. Abraham, Seth A. Wander, S. Isakoff, B. Moy, L. Ellisen, A. Bardia   +12 more
semanticscholar   +1 more source